top of page

Search Results

Results found for "Beth Fleck"

  • Job Opportunity Spotlight #1: Principal Scientist, In Vitro Pharmacology

    As Chief Matchmaker, I recently had the pleasure of speaking with Beth Fleck, Director of In Vitro Pharmacology Mark:  “Beth, why did you decide to join Crinetics?” Beth:  “Yes.  There are a lot of learning opportunities at Crinetics.  Mark:  “Beth, why would someone want you as their boss?” Beth:  “Well, I enjoy training and mentoring team members. 

  • 📰 GPCR Weekly News, May 20 to 26, 2024

    Mark recently discussed this exciting opportunity with Beth Fleck, Director of In Vitro Pharmacology

  • 📰 GPCR Weekly News, April 22 to 28, 2024

    Our Chief Matchmaker, Mark Schmeizl, had a great conversation about this position with Beth Fleck, Director

  • 📰 GPCR Weekly News, April 15 to 21, 2024

    Our Chief Matchmaker, Mark Schmeizl, had a great conversation about this position with Beth Fleck, Director

  • 📰 GPCR Weekly News, May 13 to 19, 2024

    Stay tuned for further details, as we plan to open registrations for both courses in July 2024. Dr. Mark discussed this position with Beth Fleck, Director of In Vitro Pharmacology at Crinetics Pharmaceuticals

  • C3aR plays both sides in regulating resistance to bacterial infections

    regarding the role of C3aR in controlling bacterial infections and analyze these results in the context of both

  • Expression pattern and clinical significance of beta 2-adrenergic receptor in oral squamous cell...

    September 2022 Expression pattern and clinical significance of beta 2-adrenergic receptor in oral squamous cell carcinoma: an emerging prognostic indicator and future therapeutic target "Purpose: Beta 2-Adrenergic

  • Use of CRISPR/Cas9-edited HEK293 cells reveals that both conventional and novel protein kinase C...

    October 2022 Use of CRISPR/Cas9-edited HEK293 cells reveals that both conventional and novel protein PKC and mutation of rat mGlu5a Ser901, a PKC-dependent phosphorylation site in the receptor C-tail, both This indicates that isozymes from both classes are involved, compensate for the absence of the other

  • A role for BET proteins in regulating basal, dopamine-induced and cAMP/PKA-dependent ...

    A role for BET proteins in regulating basal, dopamine-induced and cAMP/PKA-dependent transcription in One candidate effector of PKA-dependent transcriptional regulation is the BET protein Brd4. However, it is unknown whether BET proteins, or Brd4 specifically, are involved in transcriptional activation Here, we demonstrate that in adult rats, inhibition of BET proteins with the bromodomain inhibitor JQ1 Our findings identify the BET protein family, and Brd4 in particular, as novel regulators of basal and

  • Innovative Data-Driven Solutions: The pHSense Revolution

    Eric Trinquet, that moment arrived when his team successfully tracked GPCR internalization in native beta They learned how to fine-tune both brightness and fluorescence lifetime. transformed everything: a clean, dose-dependent response of GLP-1 receptor internalization in native beta synthesis begins Collaborative screening of scaffold families Key milestone: Clean signal in endogenous beta

  • Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies

    September 2022 "Research on cancer therapies focuses on processes such as angiogenesis, cell signaling, stemness, metastasis, and drug resistance and inflammation, all of which are influenced by the cellular and molecular microenvironment of the tumor. Different strategies, such as antibodies, small chemicals, hormones, cytokines, and, recently, gene editing techniques, have been tested to reduce the malignancy and generate a harmful microenvironment for the tumor. Few therapeutic agents have shown benefits when administered alone, but a few more have demonstrated clear improvement when administered in combination with other therapeutic molecules. In 2008 (and for the first time in the clinic), the therapeutic benefits of the β-adrenergic receptor antagonist, propranolol, were described in benign tumors, such as infantile hemangioma. Propranolol, initially prescribed for high blood pressure, irregular heart rate, essential tremor, and anxiety, has shown, in the last decade, increasing evidence of its antitumoral properties in more than a dozen different types of cancer. Moreover, the use of propranolol in combination therapies with other drugs has shown synergistic antitumor effects. This review highlights the clinical trials in which propranolol is taking part as adjuvant therapy at single administration or in combinatorial human trials, arising as a good pick and roll partner in anticancer strategies." Read more at the source #DrGPCR #GPCR #IndustryNews

  • From Ox Liver to AI: How the History of Pharmacology Shapes Its Future

    They both mark critical moments in humanity’s centuries-long quest to control physiology—and they bookend Fast-forward a few thousand years, and we’re talking beta receptors, receptor theory, and AI-generated

  • How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs

    Instead of chasing linear progress, Eric encourages young scientists to stay playful longer—embracing both 2023: pHSense probes optimized for dual pH response ✅ 2024: Endogenous GLP-1 internalization shown in beta moment with pHSense came the day his team showed internalization of endogenous GLP-1 receptors in rat beta

  • Maria’s Travel Blogs: ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025

    to the US to attend the ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025 , a conference organized by both the EFMC and the ACSMEDI, in an effort to share the most novel medicinal chemistry advancements in both This joint effort by both associations is repeated every year, with 2026’s being in Dublin, Ireland. The talks given targeted both traditional GPCRs such as the serotoninergic receptor 5HT1A, but also newer

  • Terry’s Corner, Celtarys' Leap, and the $7B GPCR Horizon

    in β-arrestin recruitment across class B1 GPCRs  – GPCR mutations in cancer—drivers, passengers, or both Research presents CELT-419, a nanomolar-affinity fluorescent ligand optimized for D3 receptor assays in both GPCR mutations in cancer   show both driver-like patterns and high redundancy, prompting a call for multiomics

  • Applications of Fluorescent Probes in Confocal Imaging of GPCRs: From Live to Fixed Cells

    Studying their dynamics in both a spatial and temporal manner is key to understanding how they work in fluorescent probes must have high specificity, minimal phototoxicity and preferably be compatible with both This is why fluorescent tags, both attached to the protein or to pharmacophores, are so interesting. image stacks, facilitating the reconstruction of GPCR distribution in tissue-like environment , in both

  • GPCR Happy Hour – Boston, Sept 2025

    Matters Connect with peers across biotech, CROs, and investment who are driving discovery forward Meet both identification, target validation, assay development, compound management, and high-throughput screening in both Screening campaigns can be performed using Axxam’s high-quality compound collections—both synthetic and

  • Orthosteric vs Allosteric Interactions— and the pHSense Shift in Internalization

    Eric Trinquet and his team at Revvity, that moment came when they watched GPCRs internalize in native beta By carefully tuning both brightness and fluorescence lifetime, they engineered a two-dimensional pH response receptor localization and real-time signaling shape therapeutic outcomes, fluorescent ligands deliver both

  • The Quiet Power of RGS Proteins: Rethinking Pain Pathways through GPCR Biology

    Serafini noted that RGS4 was especially intriguing because it was expressed robustly both in the peripheral system and in central circuits like the prefrontal cortex and thalamus  — areas deeply involved in both

  • Class B1 GPCR Dimerization: Unveiling Its Role in Receptor Function and Signaling

    C GPCRs, are obligate dimers, either as homodimers or heterodimers, with distinct conformations in both Recent studies suggest that class B1 GPCRs can form both homodimers and heterodimers, which may play that GLP-1R homodimerization occurs via transmembrane helix 4 (TM4), which forms the interface for both result, dimerized SecR receptors exhibit higher rates of G protein activation and release, improving both

  • New role of β-arrestins in MOR signaling

    receptors belong to class A of G protein-coupled receptors or GPCRs and signaled mainly through Gai/o, beta At the synapse, they are localized in both pre- and postsynaptic compartments and their activation is The authors found that both β-arrestin 1 and 2 are involved in MOR internalization and downstream signaling

  • Co-activation of GPCRs facilitate GIRK-dependent current

    October 2022 "The activity of dopamine neurons is dependent on both intrinsic properties and afferent applications of sub-saturating concentrations of agonists where the co-application of one agonist resulted in both results suggest that the cooperative interaction between G βγ subunits and GIRK channels determines both Coincident activation of D2 and GABAB receptors leads to facilitation of GIRK channel currents, augmenting both

  • Ever Wondered How Drugs Are Discovered?

    why teamwork is non-negotiable) The difference between Me Too  and First in Class  projects—and why both

  • 📰 GPCR Weekly News, December 4 to 10, 2023

    Registrations open on December 15th and close on February 1st to both Dr. GPCR Activation and Signaling Distinct beta-arrestin coupling and intracellular trafficking of metabotropic

  • Optimizing HTRF Assays with Fluorescent Ligands: Time-Resolved Fluorescence in GPCR Research

    Measuring emission at both donor (usually 620nm) and acceptor (typically 665nm) wavelengths allows for Terbium is compatible with both red and green acceptors. expertise in GPCR biology with advanced fluorescence chemistry, Celtarys custom-developed ligands offer both

  • Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST2 and SST5...

    The cytoskeletal protein filamin A (FLNA) directly interacts with both somatostatin receptor type 2 ( A7), and octreotide but not pasireotide promoted hetero-dimerization in both A7 and M2 (+20.0 ± 11.8% On the contrary, in M2 cells, octreotide failed to internalize both receptors whereas pasireotide promoted In conclusion, we demonstrated that in GH3 cells SST2 and SST5 can form both homo- and hetero-dimers

  • Isoforms of GPR35 have distinct extracellular N-termini that allosterically modify...

    Additionally, we employed optical assays in living cells to thoroughly profile both GPR35 isoforms for basis for this bias, we examined structural models of GPR35 and conducted experiments with mutants of both found that a proposed disulfide bridge between the N-terminus and extracellular loop 3, present in both

  • Lack of Oestrogen Receptor Expression in Breast Cancer Cells Does Not Correlate with Kisspeptin...

    However, controversy remains regarding its role in breast cancer since both pro- and anti-metastatic We show that both cell lines express KISS1R mRNA and respond to KP-10 by elevating calcium mobilisation Interestingly, both cell lines displayed different complements of β-arrestin 1 and 2 expression.

  • Nanobodies as Probes and Modulators of Cardiovascular G Protein-Coupled Receptors

    single-domain antibody fragments from camelids, have become indispensable tools for interrogating GPCRs both technologies to discover nanobodies with tailored specificities may expand the impact of these tools for both

  • The Adhesion GPCR VLGR1/ADGRV1 Regulates the Ca2+ Homeostasis at Mitochondria-Associated ER Membrane

    proteomics revealed that in the interactome of VLGR1, molecules are enriched that are associated with both mitochondria, as well as mitochondria-associated ER membranes (MAMs), a compartment at the contact sites of both

bottom of page